Biopartnering Seminar Series - Aducanumab - By Team 99
Abstract: Polygenic risk scores (PRS), derived from genome-wide association studies (GWAS), are an up and coming tool in precision/personalized medicine. How might they be leveraged by Biogen, who has just filed a BLA for Aducanumab, a monoclonal antibody (mAb) for the treatment for Alzheimer’s disease?
Alzheimer’s disease (AD) is a chronic, irreversible neurodegenerative disease that causes cognitive function and behavioral abilities to deteriorate over time. Biogen has recently filed a Biologics License Application (BLA) in the United States for Aducanumab, a monoclonal antibody that clears amyloid plaques in the brain, as a potential treatment for AD. Using a dementia-specific genome sequencing panel, Biogen can further develop and market Aducanumab by conducting an observational pilot study on patients with AD and patients at risk of developing AD. Patients at the Baycrest Memory clinic who have been diagnosed with probable AD, along with their first-degree relatives who accompany the primary patients to their appointments, will participate in the study. Data collected will include patient demographics and co-morbidities, genome sequencing data focused on clinically validated AD gene variants, and cognitive assessments via Baycrest’s Cogniciti tool. Additionally, surveys were conducted with patients and their caregivers to collect information about the patient experience. Our study will provide Biogen with data from high-risk patients prior to their development of AD. Used within statistical modelling, this data will allow for better targeting and segmentation in their marketing, as well as provide supplemental data for Biogen.
(Access Passcode: s7#+sg!xAU)